CLRBライブシグナル | Getagraph.comで利益を最大化

売る 109472 min ago

@ $3.47

発行日: 14 2月 2024 @ 01:14

リターン: -9.51%

前回のシグナル: 2月 7 - 23:31

前回のシグナル: 買う

リターン: -0.86 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:46):

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer...

Stats
本日の出来高	398 429
平均出来高	1.04M
時価総額	101.30M
EPS	$0 ( 2024-03-27 )
次の収益日	( $-0.500 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.010
ATR14	$0.0110 (0.35%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-23	Lea Darrell Shane	Buy	100 000	Stock option (right to buy)
2023-12-08	Lea Darrell Shane	Buy	39 599	Common Stock
2023-06-23	Kolean Chad J	Buy	104 000	Stock option (right to buy)
2023-12-08	Kolean Chad J	Buy	42 554	Common Stock
2023-12-08	Shustov Andrei	Buy	47 856	Common Stock

INSIDER POWER
100.00
Last 93 transactions
Buy: 8 845 700 \| Sell: 235 734

ボリューム相関

長: 0.01 (neutral)

短: -0.42 (neutral)

Signal:(45.647) Neutral

Cellectar Biosciences Inc 相関

10 最も正の相関
CNTX	0.857
AIP	0.849
AMWD	0.841
PLAB	0.841
AMTX	0.832
RCMT	0.831
EBIX	0.825
PRIM	0.824
CSWI	0.822
JSML	0.818

10 最も負の相関
AMRB	-0.847
NVEI	-0.809

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Cellectar Biosciences Inc 相関 - 通貨/商品

0.49
( neutral )

0.54
( weak )

0.00
( neutral )

0.41
( neutral )

0.60
( weak )

-0.48
( neutral )

Cellectar Biosciences Inc 財務諸表

Annual	2023
収益:	$0
総利益:	$-192 375 (0.00 %)
EPS:	$-3.11

FY	2023
収益:	$0
総利益:	$-192 375 (0.00 %)
EPS:	$-3.11

FY	2022
収益:	$0
総利益:	$-238 867 (0.00 %)
EPS:	$-4.05

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-4.30

Financial Reports:

No articles found.

Cellectar Biosciences Inc

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

リアルタイムの更新： Cellectar Biosciences Inc [CLRB]

Upcoming Earnings Alert